Chardan Capital analyst Keay Nakae reiterated a Buy rating on ProQR (PRQR) today and set a price target of $25. The company’s shares closed yesterday at $11.05.
According to TipRanks.com, Nakae is ranked 0 out of 5 stars with an average return of -15.1% and a 31.6% success rate. Nakae covers the Healthcare sector, focusing on stocks such as Arbutus Biopharma Corporation, Arcturus Therapeutics Ltd, and BioSig Technologies Inc.
Currently, the analyst consensus on ProQR is a Strong Buy with an average price target of $28.33.
See today’s analyst top recommended stocks >>
The company has a one-year high of $24 and a one-year low of $4.35. Currently, ProQR has an average volume of 225.4K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
ProQR Therapeutics NV operates as a biopharmaceutical company, which engages in the discovery and development of Ribonucleic Acid RNA based therapeutics for the treatment of genetic disorders. Its initial focus is on the development of a disease-modifying therapy for the treatment of cystic fibrosis.
